Latest News and Press Releases

Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA...

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million ...

RAMSEY, N.J. and BOCA RATON, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 ...

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately...

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for...

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...